The mission of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the United States Food and Drug Administration (FDA) is to identify, prioritize, sponsor, coordinate, and promote innovative activities — with a special interest in optimizing clinical trials — that will expedite the discovery and development of improved analgesic, anesthetic, and addiction treatments for the benefit of the public health.

ACTTION is a multi-year, multi-phase initiative that is closely aligned with the FDA's Critical Path Initiative. This public-private partnership has been designed to streamline the discovery and development process for new analgesic, anesthetic, and addiction medications and to more generally accelerate the development of treatments with improved efficacy and safety.

The key objectives of ACTTION involve initiating and supporting strategic collaborations among a broad spectrum of stakeholders — including, but not limited to, academia, the FDA and other government agencies, industry, professional organizations, patient advocacy groups, foundations, and philanthropic organizations — with the goals of sharing data and innovative thinking about the development of novel therapeutics. These strategic collaborations involve a wide range of research projects and other activities, for example, scientific workshops, consensus meetings, and in-depth analyses of clinical trial data to determine the effects of research methods on study assay sensitivity and efficiency.

ACTTION is intended to have benefits that are international in scope. To represent the bridges that ACTTION is establishing among its diverse stakeholders, this website is illustrated with watermarks of two bridges that share the distinction of connecting different continents. Directly below is the First Bosphorus Bridge in Istanbul, Turkey, which connects Europe and Asia; on the Contact Us webpage is the Leifur Eiriksson Bridge in Iceland's Reykjanes peninsula, which spans a rift valley between the North American and European continental plates.


May 22, 2014: Six ACTTION Articles Published or Accepted Since January 1, 2014

The following six ACTTION articles have been published or accepted for publication since January 1, 2014. These articles cover a range of topics, as can be seen from their titles, and abstracts are available at the link provided at the end of each reference.

1. Fillingim RB, Bruehl S, Dworkin RH, Dworkin SF, Loeser JD, Turk DC, Widerstrom-Noga E, Arnold L, Bennett R, Edwards RR, Freeman R, Gewandter J, Hertz S, Hochberg M, Krane E, Mantyh PW, Markman J, Neogi T, Ohrbach R, Paice JA, Porreca F, Rappaport BA, Smith SM, Smith TJ, Sullivan MD, Verne GN, Wasan AD, Wesselmann U. The ACTTION-American Pain Society Pain Taxonomy (AAPT): an evidence-based and multidimensional approach to classifying chronic pain conditions. Journal of Pain, 2014;15:241-249. (abstract here)

2. Gewandter JS, Smith SM, McKeown A, Burke LB, Hertz SH, Hunsinger M, Katz NP, Lin AH, McDermott MP, Rappaport BA, Williams MR, Turk DC, Dworkin RH. Reporting of primary analyses and multiplicity adjustment in recent analgesic clinical trials: ACTTION systematic review and recommendations. Pain, 2014;155:461-466. (abstract here)

3. Hunsinger M, Smith SM, McKeown A, Parkhurst M, Gross RA, Lin AH, McDermott MP, Rappaport BA, Turk DC, Dworkin RH. Disclosure of authorship contributions in analgesic clinical trials and related publications: ACTTION systematic review and recommendations. Pain, 2014;155:1059-1063. (abstract here)

4. Farrar JT, Troxel AB, Haynes K, Gilron I, Kerns RD, Katz NP, Rappaport BA, Rowbotham MC, Turk DC, Dworkin RH. The effect of variability in the 7 day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: an ACTTION study. Pain, in press. (abstract here)

5. Gewandter JS, Dworkin RH, Turk DC, McDermott MP, Baron R, Gastonguay M, Gilron I, Katz NP, Mehta C, Raja SN, Senn S, Taylor C, Cowan P, Desjardins P, Dimitrova R, Dionne R, Farrar JT, Hewitt DJ, Iyengar S, Jay GW, Kalso E, Kerns RD, Leff RL, Leong M, Petersen KL, Ravina BM, Rauschkolb C, Rice ASC, Rowbotham MC, Sampaio C, Sindrup SH, Stauffer JW, Steigerwald I, Stewart J, Tobias J, Treede RD, Wallace M, White RE. Research design considerations for proof-of-concept chronic pain clinical trials: IMMPACT recommendations. Pain, in press. (abstract here)

6. Munch M, Dufka FL, Greene K, Smith SM, Dworkin RH, Rowbotham MC. RReACT goes global: perils and pitfalls of constructing a global open-access database of registered analgesic clinical trials and trial results. Pain, in press. (abstract here)

May 20, 2014: IMMPACT Website Now Includes Presentations and Transcript from Physical Functioning Meeting

The IMMPACT website ( has now been updated to include the background slide presentations from the April 17-18, 2014 IMMPACT meeting on "Assessment of Physical Functioning in Analgesic Clinical Trials." We have also begun to include transcripts prepared from audio recordings of all IMMPACT and ACTTION meetings on the websites, and a transcript of this meeting will soon be available on the IMMPACT website.

May 5, 2014: Update from American Pain Society Meeting, including Bonica Public Service Award

ACTTION was very active at the annual meeting of the American Pain Society, held in Tampa, Florida from April 30-May 3, 2014. There was a symposium chaired by Dr. Dennis Turk focusing on the activities of the Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT) working group with presentations by Drs. Richard Dart, Bob Rappaport, and Shannon Smith, a presentation on ACTTION’s activities related to analgesic clinical trial assay sensitivity by Dr. Robert Dworkin at the meeting of the Clinical Trials Special Interest Group, two poster presentations by Dr. Jennifer Gewandter, and one poster presentation by Dr. Matthew Hunsinger.

In addition, Drs. Turk and Dworkin received the John and Emma Bonica Public Service Award in recognition of IMMPACT’s "distinguished contributions through public education, dissemination of information, public service, and other efforts to further knowledge about pain." (see award presentation here)